BlackRock Advisors’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

BlackRock Advisors’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$101K	Sell	742 -31	-4%	-$5.5K	﹤0.01%	3037
2016 Q3	$154K	Buy	773 +139	+22%	+$23.9K	﹤0.01%	2817
2016 Q2	$82K	Buy	634 +384	+154%	+$42.7K	﹤0.01%	3057
2016 Q1	$23K	Buy	250 +48	+24%	+$5.23K	﹤0.01%	3406
2015 Q4	$41K	Sell	202 -176	-47%	-$31.5K	﹤0.01%	3276
2015 Q3	$55K	Sell	378 -51	-12%	-$9.36K	﹤0.01%	3295
2015 Q2	$91K	Buy	429 +43	+11%	+$10.5K	﹤0.01%	3204
2015 Q1	$89K	Buy	+386	New	+$93.4K	﹤0.01%	3094

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

BlackRock Advisors's BLCM Position: Q4 2016 in Review

BlackRock Advisors reduced its Bellicum Pharmaceuticals, Inc. (BLCM) stake by 4% in Q4 2016, selling an estimated $5.5K and leaving 742 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #3037.

BlackRock Advisors first reported a position in BLCM in Q1 2015 and has held it in 8 quarters since. The position peaked at $154K in Q3 2016. 80 funds tracked by Wall St. Rank hold BLCM as of Q4 2016.

BlackRock Advisors held 742 shares of Bellicum Pharmaceuticals, Inc. worth $101K as of Q4 2016.
BlackRock Advisors sold 31 Bellicum Pharmaceuticals, Inc. shares in Q4 2016, an estimated $5.5K.
Bellicum Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3037 holding.
BlackRock Advisors first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2015 and has held it in 8 quarters since.
BlackRock Advisors's Bellicum Pharmaceuticals, Inc. position peaked at $154K in Q3 2016.
80 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.